266 related articles for article (PubMed ID: 26457375)
21. The contemporary management of systemic sclerosis.
Eldoma M; Pope J
Expert Rev Clin Immunol; 2018 Jul; 14(7):573-582. PubMed ID: 29874475
[TBL] [Abstract][Full Text] [Related]
22. [Systemic sclerosis].
Peltomaa R; Pettersson T; Tuompo R; Luosujärvi R
Duodecim; 2013; 129(19):1981-91. PubMed ID: 24218729
[TBL] [Abstract][Full Text] [Related]
23. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.
Asano Y; Varga J
Semin Cell Dev Biol; 2020 May; 101():146-160. PubMed ID: 31859147
[TBL] [Abstract][Full Text] [Related]
24. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
Hasegawa M; Takehara K
Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
[TBL] [Abstract][Full Text] [Related]
25. Emerging targeted therapies in scleroderma lung and skin fibrosis.
Maurer B; Distler O
Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast abnormalities in the pathogenesis of systemic sclerosis.
Usategui A; del Rey MJ; Pablos JL
Expert Rev Clin Immunol; 2011 Jul; 7(4):491-8. PubMed ID: 21790292
[TBL] [Abstract][Full Text] [Related]
27. New pathogenic and therapeutic concepts in systemic sclerosis.
Hügle T; Huigens CA; van Laar JM
Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
[TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis.
Wei J; Bhattacharyya S; Varga J
Curr Opin Rheumatol; 2010 Nov; 22(6):671-6. PubMed ID: 20693905
[TBL] [Abstract][Full Text] [Related]
29. [Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment].
Sicińska J; Rudnicka L
Pol Merkur Lekarski; 2008 Aug; 25(146):192-5. PubMed ID: 18942346
[TBL] [Abstract][Full Text] [Related]
30. Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis.
Elisa T; Antonio P; Giuseppe P; Alessandro B; Giuseppe A; Federico C; Marzia D; Ruggero B; Giacomo M; Andrea O; Daniela R; Mariaelisa R; Claudio L
J Immunol Res; 2015; 2015():147616. PubMed ID: 26090478
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
Luo Y; Wang Y; Shu Y; Lu Q; Xiao R
Int J Biochem Cell Biol; 2015 Oct; 67():92-100. PubMed ID: 26043891
[TBL] [Abstract][Full Text] [Related]
32. Potential use of TNF-α inhibitors in systemic sclerosis.
Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F
Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073
[TBL] [Abstract][Full Text] [Related]
33. Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment.
Sahhar J; Littlejohn G; Conron M
Intern Med J; 2004 Nov; 34(11):626-38. PubMed ID: 15546457
[TBL] [Abstract][Full Text] [Related]
34. Pharmacotherapy of systemic sclerosis.
Postlethwaite AE; Harris LJ; Raza SH; Kodura S; Akhigbe T
Expert Opin Pharmacother; 2010 Apr; 11(5):789-806. PubMed ID: 20210685
[TBL] [Abstract][Full Text] [Related]
35. Use of methotrexate in patients with scleroderma and mixed connective tissue disease.
Kowal-Bielecka O; Distler O
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S160-3. PubMed ID: 21044452
[TBL] [Abstract][Full Text] [Related]
36. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis.
Leask A
Pharmacol Res; 2011 Jun; 63(6):502-3. PubMed ID: 21315153
[TBL] [Abstract][Full Text] [Related]
37. Targeting interferons as a strategy for systemic sclerosis treatment.
Ciechomska M; Skalska U
Immunol Lett; 2018 Mar; 195():45-54. PubMed ID: 29106987
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in the diagnosis and treatment of systemic sclerosis.
Kowal-Bielecka O; Bielecki M; Kowal K
Pol Arch Med Wewn; 2013; 123(1-2):51-8. PubMed ID: 23344666
[TBL] [Abstract][Full Text] [Related]
39. Advances in pathogenesis and treatment of systemic sclerosis.
Denton CP
Clin Med (Lond); 2015 Dec; 15 Suppl 6():s58-63. PubMed ID: 26634684
[TBL] [Abstract][Full Text] [Related]
40. Novel investigational agents for the treatment of scleroderma.
McMahan ZH; Wigley FM
Expert Opin Investig Drugs; 2014 Feb; 23(2):183-98. PubMed ID: 24261610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
